Act4Biosimilars Vision A world in which patients have increased access to biologics by helping to accelerate biosimilar approvability, accessibility, acceptability and affordability. Act4Biosimilars Mission To increase the global adoption of biosimilars by at least 30% in 30+ countries by 2030. Act4Biosimilars Steering Committee Jorge J. García PharmD, MS, MHA, MBA, FACHE Assistant Vice PresidentSystem Oncology Pharmacy Service Line "My priority for A4B is… to relate economic and scientific evidence supporting the safe and effective use of biosimilars to increase global access of high-quality biologics at a fraction of the cost." Jorge García currently serves as Assistant Vice President at Baptist Health South Florida, where he is responsible for oncology pharmacy services, non-oncology infusion pharmacy services, and sterile compounding quality. Throughout his career, Jorge has been a pioneer for pharmacy charge integrity and revenue management in the health system setting and is also a thought leader in the areas of alternative payment models, biosimilars, drug bagging practices, and value-based care. Jorge leads advocacy efforts at the national level to promote evaluation of safe and effective use of biosimilars, along with increasing stakeholder engagement to support a more sustainable biosimilar pharmacoeconomic model. He currently holds multiple board and committee appointments, including roles at the Association of Community Cancer Centers, the Florida Society of Clinical Oncology, and the American Pharmacists Association, among others. Jorge is a fellow of the American College of Healthcare Executives. Sean Grande Vice President of Healthcare AccessNational Multiple Sclerosis Society “My priority for A4B is... to address the systemic barriers and market dynamics that prevent individuals from accessing safe, effective treatment options at significant cost savings.” Sean Grande serves as Vice President of Healthcare Access at the National Multiple Sclerosis (MS) Society, where he works to ensure that the one million people living with MS in the U.S. today have access to affordable, high-quality care. Prior to joining the Society, he served as Principal of Health Strategy at League Inc. and as Chief of Staff for the Aetna One Advocate program at CVS Health. He has also held senior-level roles at the American Osteopathic Association and Health Care Service Corporation, where he led a variety of policy reform initiatives spanning the public and private sectors. His earlier experience includes employment in the Office of the Executive Director and the Office of the Chief Science Officer at the Patient-Centered Outcomes Research Institute (PCORI), serving on Aetna’s federal affairs team, and working as a federal lobbyist for a large human resources association. A Buffalo, NY native and current resident of Chicago, IL, he holds a bachelor’s degree from Allegheny College and a master’s degree from Johns Hopkins. Prof. Tore Kvien Head of Department of Rheumatology University of Oslo, Norway “My priority for A4B is... to improve the understanding of biosimilars as an opportunity to improve access for patients to biological disease-modifying antirheumatic drugs (DMARDs) at a lower cost.” Tore Kvien has been a Professor of Rheumatology at the University of Oslo since 1997, and currently holds a position as senior researcher and research advisor at the Diakonhjemmet Hospital after serving as the Head of the Department of Rheumatology up until 2019. His major research activities include therapeutic strategy trials with a focus on frequently occurring diseases such as rheumatoid arthritis, osteoarthritis, and spondyloarthritis. Tore is also the leader of the Norwegian NOR-DMARD registry and was the principal investigator of the Norwegian government funded NOR-SWITCH trial. He has published more than 600 original research articles in international peer-reviewed journals, and previously served as the President of EULAR and Editor-in-Chief at the Annals of the Rheumatic Diseases. Tore has received numerous accolades, including the EULAR Meritorious Service Award in 2017, the Carol Nachman Medal in 2018, and an appointment as Officer First Class of the Royal Order of St Olav by the King of Norway in 2019. Zorana Maravic CEODigestive Cancers Europe “My priority for A4B is... to address education and communication with a multistakeholder approach to help patients and HCPs feel comfortable about biosimilars and understand its value in improving patient care." Zorana Maravic is the CEO of Digestive Cancers Europe (previously EuropaColon), the first and only European digestive cancers patient umbrella organization. She is responsible for all day-to-day management and spearheads delivery of the organization’s goals. In her previous role as Director of Operations, Zorana was responsible for the coordination of member groups, and strengthened the organization’s network by establishing relationships with new groups and individuals. Zorana is also a public speaker on topics such as patient support, biosimilars, and colorectal cancer screening. Before entering the not-for-profit sector Zorana accumulated 10 years’ experience in the pharmaceutical industry, primarily in sales and marketing of innovative oncology drugs as well as in oncology clinical trials. She holds a degree in Molecular Biology from the University of Belgrade and an MBA in Health Management from the University of Sheffield. Margaret Rehayem Vice PresidentNational Alliance of Healthcare Purchasers “My priority for A4B is... to bring the employer voice into this important conversation on the affordability and accessibility of biosimilars.” Margaret Rehayem is the Vice President of the National Alliance of Healthcare Purchaser Coalitions, which is the only not-for-profit, purchaser-led organization with a national and regional structure dedicated to driving healthcare value across the U.S. Within her role she spearheads national initiatives that support member collaboration, leveraging regional efforts to the national level in the areas of delivery and payment reform, health policy, and total person health. Throughout her career she has developed multi-stakeholder learning collaboratives, continuous improvement frameworks, and has led multiple projects in the areas of healthcare planning and drug management, including on biosimilars. She has over 20 years' experience working with employers and regional coalitions across the country and has served on various advisory boards focused on quality and care delivery improvement. Prof. Arnold Vulto Independent Consultant and EducatorVuPEC “My priority for Act4Biosimilars is... that with biosimilars we can increase access to biological therapies for patients and contribute to a better and more affordable healthcare.” Arnold Vulto is a co-founder of the Generics & Biosimilars Initiative and the Initiative Group of Biosimilars in the Netherlands. In 2015, he also initiated and chaired the First National Conference on Biosimilars in the Netherlands. Previously, Arnold trained as a pharmacist at the University of Groningen, later specializing in hospital pharmacy and obtaining his PhD from the University of Utrecht. He was appointed Head of the Hospital Pharmacy of the Veterinary Faculty at the University of Utrecht in 1988, later moving to the Erasmus University Medical Centre in Rotterdam. Arnold is the recipient of multiple awards, most notably the Visionary Guidance and Leadership Award in Hospital Pharmacy and the Jan Glerum Lifetime Achievement Award for his contribution to the field. He holds honorary professorships at the Erasmus MC and the Catholic University in Leuven, as well as a Dutch Knighthood. In 2019, he was elected lifetime honorary member of the Dutch Association of Hospital Pharmacists. Prof. Dr. Michael Wiechmann Global Head Medical AffairsSandoz “My priority for A4B is... to increase access for patients to highly effective and affordable biologics to improve their outcome and support sustainability of healthcare systems.” Michael Wiechmann is the Global Head of Medical Affairs at Sandoz Biopharmaceuticals (a Novartis division), where he is responsible for the entire spectrum of medical affairs with a special focus on strategic development, launch excellence, real world evidence generation and digitization of medical affairs. Prior to joining Sandoz, Michael founded a biotech company and has held several leadership positions in global medical affairs and among top management in pharmaceutical, biotech and health insurance companies. Michael is a MD by training with specialization in internal medicine and haemato-oncology and holds an MBA and PhD in Health Economics and Business Administration. He is an associate professor for Healthcare Management at the Apollon University in Bremen. Laura D. Wingate Executive Vice President, Education, Support & Advocacy Crohn’s & Colitis Foundation “My priority for A4B is to ensure access to biosimilars through education, awareness and engagement with insurers, patients and healthcare professionals.” Laura Wingate is the Executive Vice President, Education, Support, & Advocacy of the Crohn’s & Colitis Foundation, dedicated to finding cures for Crohn’s disease and ulcerative colitis and improving the lives of children and adults affected by these diseases. She is responsible for patient and professional education, state and federal advocacy, and supports programming for the Foundation. She began her career working at Memorial Sloan Kettering Cancer Center where she advised and implemented quality improvement initiatives, including redesigning the outpatient center focused on streamlining the patient’s experience. She also worked with pediatric and geriatric centers across the United States, providing professional entertainers through the Clown Care and Vaudeville Caravan programs which expanded dramatically over her eight-year tenure. She is a graduate of the University of Rochester, School of Arts & Sciences. Together, as Members of the Act4Biosimilars Steering Committee, We Pledge to… Accelerate the biosimilars movement by increasing awareness of the benefits that better access to biosimilars brings to patients; and clarifying the pathways that will achieve this goal. Drive new thinking, high-quality analysis, reflection, and evidence-based outputs to support the increased adoption of biosimilars generated by Act4Biosimilars – including participation in professional fora and debates, knowledge sharing, educational actions, and the publication of authoritative papers and reports. Work together to help spread the word of the opportunities and benefits that greater patient access to biosimilars brings, and how current barriers to progress can be addressed in a positive way. Keep patients at the center of everything we do, as we clearly define what success looks like, and set impact and performance goals to track the progress of Act4Biosimiliars.